Liège, Belgium 21 October 2015 – Mithra Pharmaceuticals SA/NV announced that it has signed an agreement with Chiltern for the Phase II dose-finding study of its Estetrol-base product candidate Donesta®, a hormonal replacement therapy for menopausal women. This study called E4Relief is expected to start H1 2016 and to be finished end 2016. This contract amounts to EUR 4,5 million.
Share it
Latest news
Mithra announces updates to its 2024 financial calendar
28 March 2024
Mithra reports full year 2023 financial results
8 March 2024